Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,609 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ. Min A, et al. Among authors: kim hj, kim ty, kim dk. Breast Cancer Res. 2015 Mar 7;17:33. doi: 10.1186/s13058-015-0534-y. Breast Cancer Res. 2015. PMID: 25888415 Free PMC article.
Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Keam B, et al. Among authors: kim hj, kim dw, kim ty, kim jh. BMC Cancer. 2007 Nov 1;7:203. doi: 10.1186/1471-2407-7-203. BMC Cancer. 2007. PMID: 17976237 Free PMC article.
Clinical significance of axillary nodal ratio in stage II/III breast cancer treated with neoadjuvant chemotherapy.
Keam B, Im SA, Kim HJ, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Cho N, Moon WK, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ. Keam B, et al. Among authors: kim hj, kim dw, kim ty, kim jh. Breast Cancer Res Treat. 2009 Jul;116(1):153-60. doi: 10.1007/s10549-008-0160-9. Epub 2008 Sep 12. Breast Cancer Res Treat. 2009. PMID: 18787948 Clinical Trial.
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatment.
Kim HJ, Im SA, Keam B, Kim YJ, Han SW, Kim TM, Oh DY, Kim JH, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Noh DY, Heo DS, Park IA, Bang YJ, Ha SW. Kim HJ, et al. Among authors: kim yj, kim dw, kim ty, kim tm, kim jh. J Neurooncol. 2012 Jan;106(2):303-13. doi: 10.1007/s11060-011-0664-8. Epub 2011 Sep 22. J Neurooncol. 2012. PMID: 21938531
A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH, Kim JY, Lee MH, Han HS, Lim JH, Park KU, Park IH, Cho EK, Yoon SY, Kim JH, Choi IS, Park JH, Choi YJ, Kim HJ, Jung KH, Kim SY, Oh DY, Im SA. Lee KH, et al. Among authors: kim jy, kim hj, kim sy, kim jh. Support Care Cancer. 2016 Apr;24(4):1709-17. doi: 10.1007/s00520-015-2963-7. Epub 2015 Oct 1. Support Care Cancer. 2016. PMID: 26423618 Free PMC article. Clinical Trial.
21,609 results
You have reached the last available page of results. Please see the User Guide for more information.